熱門資訊> 正文
在对铅药物的同行评审数据进行审查后，MiNK激增
2025-07-11 23:12
- 艾吉納斯(AGEN) 0
- NantKwest(NK) 0
- 纳比特(NA) 0
- Shares of MiNK Therapeutics (NASDAQ:INKT) climbed over 500% in the morning hours on Friday after the nano-cap cell therapy developer, which is a unit of Agenus (NASDAQ:AGEN), announced peer-reviewed data from a Phase 1 trial for its lead asset, agenT-797, in testicular cancer.
- The upsurge came after the New York-based biotech said that Nature’s Oncogene published a single case of complete remission in a patient with metastatic, treatment-refractory testicular cancer who received agenT-797 in its Phase 1 trial for solid tumors.
- The patient, who had been heavily pretreated, demonstrated a complete clinical, radiologic, and biochemical remission without any signs of disease over two years, the company added.
- According to the publication, the experimental therapy was found to be safe, as the patient didn’t develop cytokine release syndrome or graft-versus-host disease.
More on MiNK Therapeutics, Agenus
- Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide
- MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript
- Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript
- Agenus climbs on deal with India’s Zydus for cancer therapy BOT/BAL
- Crispr Therapeutics, Clover Health among healthcare stocks to join Russell 3000; INO, SAVA to exit
推薦文章
一周IPO丨中慧生物暗盤飆漲162%，中籤一手賺超4000港元；「減肥藥概念」銀諾醫藥招股中
一周財經日曆丨重磅財報周！騰訊京東季報輪番登場；美國7月CPI/PPI攜手「恐怖數據」來襲
機器人投資風口來襲！世界級盛會催化下，哪些機會不容錯過？
美股機會日報丨降息預期驟變！小摩稱美聯儲年內或降息三次；SoundHound飆漲超27%
摩根大通預計美聯儲將在9月會議上降息25基點，接下來還會連續三次降息
英特爾首席執行官陳立武發文：關於過往職務信息有很多錯誤 董事會全力支持公司轉型工作
美國養老金投資或迎鉅變，特朗普頒令為401(k)納入加密貨幣等資產鋪路
外盤頭條：OpenAI發佈最強GPT-5；特朗普頒令允許養老金投資另類資產
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
